SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,878.00    130.00 (4.73%)
Bid:
2,846.00
Ask:
2,862.00
Spread: 16.00 (0.562%)
Market Cap: £1.59b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Trading Update

18 Mar 2020 07:00

RNS Number : 5358G
Oxford Instruments PLC
18 March 2020
 

 

Oxford Instruments plc

Trading Update 18 March 2020

 

Oxford Instruments plc, a leading provider of high technology products and services to industrial companies and scientific research communities, is today issuing a trading update.

 

Given the current uncertainty from Covid-19 and the impact on trading, Oxford Instruments plc is issuing its pre-close for the financial year 2019/20 earlier than usual.

 

The severe disruption as a result of Covid-19 has impacted our customers, with a number of product shipments and installations in the final quarter of the financial year being delayed, in addition to an enforced site closure in California. While we are seeing some re-opening of customer sites in China, the situation in Europe and North America is deteriorating. As a result, the Group currently expects adjusted operating profit for the full year of between £47m to £50m.

 

Looking ahead, we expect current events to adversely impact trading during the first half of the financial year 2020/21, but at this stage there remains considerable uncertainty. The Group has a strong balance sheet and substantial liquidity, with net cash of over £50m. We operate in robust markets with a well-positioned portfolio of products and solutions for attractive end markets. We remain committed to our strategy and would expect trading to recover in line with a reduction in disruption from Covid-19.

 

Oxford Instruments' results for the year ended 31 March 2020 will be released on 9 June 2020.

 

Note: Oxford Instruments compiled consensus analyst forecast for adjusted operating profit (year to 31 March 2020) is £53.3m. This excludes analysts that have not updated forecasts following the disposals of OI Healthcare and our share in Scienta Omicron.

 

 

 

 

Enquiries:

 

Oxford Instruments plc Tel: 01865 393200

Ian Barkshire, Chief Executive

Gavin Hill, Group Finance Director

 

MHP Communications Tel: 020 3128 8100

Rachel Hirst/Alice McLaren

 

 

 

- Ends -

Issued for and on behalf of Oxford Instruments plc

Notes to Editors  

 

About Oxford Instruments plc

 

Oxford Instruments designs, supplies and supports high-technology tools and systems with a focus on research and industrial applications. Innovation has been the driving force behind Oxford Instruments' growth and success for 60 years, supporting its core purpose to address some of the world's most pressing challenges. 

 

The first technology business to be spun out from Oxford University, Oxford Instruments is now a global company and is listed on the FTSE250 index of the London Stock Exchange (OXIG). Its strategy focuses on being a customer-centric, market-focused Group, understanding the technical and commercial challenges faced by its customers. Key market segments include Semiconductor & Communications, Advanced Materials, Healthcare & Life Science, and Quantum Technology.

 

Their portfolio includes a range of core technologies in areas such as low temperature and high magnetic field environments; Nuclear Magnetic Resonance; X-ray, electron, laser and optical based metrology; atomic force microscopy; optical imaging; and advanced growth, deposition and etching.

 

Oxford Instruments is helping enable a greener economy, increased connectivity, improved health and leaps in scientific understanding. Their advanced products and services allow the world's leading industrial companies and scientific research communities to image, analyse and manipulate materials down to the atomic and molecular level, helping to accelerate R&D, increase manufacturing productivity and make ground-breaking discoveries.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKOBKKBKBFND
Date   Source Headline
12th Jun 20269:25 amPRNTransaction in Own Shares
9th Jun 20267:00 amRNSPreliminary Results
1st Jun 20262:03 pmPRNTotal Voting Rights
1st Jun 20261:59 pmPRNIssue of Equity
27th May 20261:58 pmPRNHolding(s) in Company
22nd May 20268:30 amPRNTransaction in Own Shares
14th May 202610:15 amPRNIssue of Equity
8th May 20268:36 amPRNTransaction in Own Shares
1st May 20269:05 amPRNTotal Voting Rights
1st May 20269:00 amPRNTransaction in Own Shares
24th Apr 20268:32 amPRNTransaction in Own Shares
17th Apr 20268:48 amPRNTransaction in Own Shares
14th Apr 202611:07 amPRNHolding(s) in Company
14th Apr 20267:00 amRNSTrading Update
13th Apr 20262:10 pmPRNHolding(s) in Company
13th Apr 20269:15 amPRNHolding(s) in Company
10th Apr 20267:00 amPRNTransaction in Own Shares
7th Apr 202611:11 amPRNTransaction in Own Shares
1st Apr 20263:26 pmPRNHolding(s) in Company
1st Apr 20262:19 pmPRNTotal Voting Rights
30th Mar 20262:54 pmPRNHolding(s) in Company
27th Mar 20268:31 amPRNTransaction in Own Shares
25th Mar 20263:15 pmPRNHolding(s) in Company
20th Mar 20269:00 amPRNTransaction in Own Shares
20th Mar 20268:00 amPRNHolding(s) in Company
17th Mar 202610:00 amPRNHolding(s) in Company
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amPRNTransaction in Own Shares
5th Mar 20262:40 pmPRNHolding(s) in Company
5th Mar 20267:00 amPRNTransaction in Own Shares
4th Mar 20267:00 amPRNTransaction in Own Shares
3rd Mar 20267:00 amPRNTransaction in Own Shares
2nd Mar 202610:38 amPRNTotal Voting Rights
2nd Mar 20267:00 amPRNExtension of Share Buyback Programme
27th Feb 20267:00 amPRNTransaction in Own Shares
26th Feb 20267:00 amPRNTransaction in Own Shares
25th Feb 20267:00 amPRNTransaction in Own Shares
24th Feb 20267:00 amPRNTransaction in Own Shares
23rd Feb 20267:00 amPRNTransaction in Own Shares
20th Feb 20267:00 amPRNTransaction in Own Shares
19th Feb 20267:00 amPRNTransaction in Own Shares
18th Feb 20267:00 amPRNTransaction in Own Shares
17th Feb 20267:00 amPRNTransaction in Own Shares
16th Feb 20267:00 amPRNTransaction in Own Shares
13th Feb 20267:00 amPRNTransaction in Own Shares
12th Feb 20267:00 amPRNTransaction in Own Shares
10th Feb 20267:00 amPRNTransaction in Own Shares
9th Feb 20267:00 amPRNTransaction in Own Shares
6th Feb 20267:00 amPRNTransaction in Own Shares
5th Feb 20267:00 amPRNTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.